Indeed, BCL6 has been involved in the pathogenesis of B-acute lymphoblastic leukemia (B-ALL), chronic myeloid leukemia (CML), breast cancer, and non-small cell lung cancer (NSCLC) [85,89,90,91], and thus its dysregulated gene expression is an attractive target for therapeutic interventions. This evidence concerns the gene BCL6 and chronic myelogenous leukemia, BCR-ABL1 positive.